Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer


Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in advanced breast cancer.

OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).

Its combination with the Pfizer breast cancer drug will be assessed in the treatment of patients having recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

See also  Mercury Systems bags $24m contract to supply avionics systems

Sean P. Bohen – President and CEO of Olema Oncology said: “This agreement with Pfizer represents continued momentum toward our goal of advancing the clinical development of OP-1250.

“We look forward to learning more about the potential of OP-1250 in combination with palbociclib in patients living with breast cancer.”

As per the terms of the non-exclusive agreement, Olema Oncology is responsible for carrying out the clinical trial, while Pfizer holds the responsibility of providing its study drug.

See also  Centerbridge Partners, GIC Real Estate to acquire Indus Realty Trust for $868m

Olema Oncology is a California-based biopharma company focused on developing targeted therapies for women’s cancers. In July 2020, the company raised $54 million in a Series B financing round, which was co-led by BVF Partners, Janus Henderson Investors, and Logos Capital.

Share This